Universe Pharmaceuticals INC
UPC
$5.94
-$1.15-16.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.28% | -1.28% | -14.14% | -14.14% | -28.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.28% | -1.28% | -14.14% | -14.14% | -28.96% |
| Cost of Revenue | -4.92% | -4.92% | -25.12% | -25.12% | -37.06% |
| Gross Profit | 5.62% | 5.62% | 16.06% | 16.06% | -6.08% |
| SG&A Expenses | -11.96% | -11.96% | -47.80% | -47.80% | 7.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.22% | -8.22% | -43.39% | -43.39% | -21.50% |
| Operating Income | 35.53% | 35.53% | 90.62% | 90.62% | -33.71% |
| Income Before Tax | 52.67% | 52.67% | 93.94% | 93.94% | 73.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.67% | 52.67% | 93.89% | 93.89% | 74.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.67% | 52.67% | 93.89% | 93.89% | 74.93% |
| EBIT | 35.53% | 35.53% | 90.62% | 90.62% | -33.71% |
| EBITDA | 38.31% | 38.31% | 94.35% | 94.35% | -37.96% |
| EPS Basic | 70.78% | 52.67% | 99.76% | 99.76% | -- |
| Normalized Basic EPS | 70.77% | 52.66% | 99.77% | 99.77% | -- |
| EPS Diluted | 70.78% | 52.67% | 99.76% | 99.76% | -- |
| Normalized Diluted EPS | 70.77% | 52.66% | 99.77% | 99.77% | -- |
| Average Basic Shares Outstanding | 61.96% | 0.00% | 2,486.70% | 2,486.70% | -- |
| Average Diluted Shares Outstanding | 61.96% | 0.00% | 2,486.70% | 2,486.70% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |